VSEE vs OPRX vs TDOC vs HCAT

For growth investors, VSee Health, Inc.

(VSEE) is the stronger pick with 80. 7% revenue growth year-over-year, versus -1. 5% for Teladoc Health, Inc. (TDOC). OptimizeRx Corporation (OPRX) offers the better valuation at 23. 9x trailing P/E (6. 8x forward), making it the more compelling value choice. Analysts rate OptimizeRx Corporation (OPRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, OptimizeRx Corporation is actually cheaper at 6.

8x.

Over the past 5 years, OptimizeRx Corporation (OPRX) delivered a total return of -85.

7%, compared to -99. 0% for VSee Health, Inc. (VSEE). Over 10 years, the gap is even starker: OPRX returned +104. 4% versus VSEE's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), VSee Health, Inc.

(VSEE) is the lower-risk stock at 1. 34β versus OptimizeRx Corporation's 2. 14β — meaning OPRX is approximately 60% more volatile than VSEE relative to the S&P 500. On balance sheet safety, OptimizeRx Corporation (OPRX) carries a lower debt/equity ratio of 4% versus 75% for Teladoc Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), VSee Health, Inc.

(VSEE) is pulling ahead at 80. 7% versus -1. 5% for Teladoc Health, Inc. (TDOC). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -1386. 8% for VSee Health, Inc.. Over a 3-year CAGR, OPRX leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

OptimizeRx Corporation (OPRX) is the more profitable company, earning 4.

7% net margin versus -553. 7% for VSee Health, Inc. — meaning it keeps 4. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 10. 7% versus -596. 4% for VSEE. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 6.

8x forward P/E versus 13. 5x for Health Catalyst, Inc. — 6. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 164. 0% to $17. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, VSee Health, Inc.

(VSEE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Health Catalyst, Inc. (HCAT) carries a higher beta of 1. 93 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VSEE: -99. 0%, HCAT: -96. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VSEE is a small-cap high-growth stock; OPRX is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock; HCAT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.